Colin Cahill joined Venrock in 2012 and focuses on Venrock’s public and cross-over biotech fund. He currently serves on the Board of Directors of RefleXion Medical and Shockwave Medical and observes on the board of 10x Genomics. Colin previously observed on the boards of Achaogen (AKAO) and Ariosa Diagnostics (acquired by Roche). Prior to joining Venrock, Colin was a co-founder and Chief Development Officer at Simpirica Spine, a Bay Area medical device company focused on the development and commercialization of devices for spinal stabilization. He served as the company’s CEO from 2006-2009. Prior to graduate school, Colin worked at the Boston Consulting Group as a strategy consultant, spent time at Boston Scientific in endosurgery clinical affairs, and worked with a variety of biotech startups in business development and operations.
Colin received an MBA from the Stanford Graduate School of Business, where he was an Arjay Miller Scholar. Prior to business school, he completed an M.S. in Biological Sciences at Stanford, during which he performed research related to cardiac cell therapy. Colin received his undergraduate degrees in Biological Sciences and Economics from Stanford University.